Unlike patients with EA, those with NEA have either high levels of other inflammatory cell types, such as neutrophils, or no dominant inflammatory cells in the airway, blood, or sputum. NEA has not been researched as much as EA, resulting in few targeted therapies for this subtype. Nonpharmacologic interventions, "off-label" use of licensed drugs, novel small molecules, and biologics agents are being investigated as possible treatments for NEA.
Learn more about the difference between EA and NEA.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Zab Mosenifar. Fast Five Quiz: Eosinophilic Asthma - Medscape - Mar 17, 2023.